CHRO Chromocell Therapeutics Corporation: Net earnings per share for the last 12 months

Chromocell Therapeutics develops advanced analgesics through virtual modeling, utilizing external CMO facilities for synthesis. However, a high concentration on ion channels creates significant binary risks for the pipeline. The one-year EPS TTM trend allows for the filtering of market noise, where serves as the base parameter value. The company's revenues will be based on the supply of non-opioid agents to clinics and insurance companies.
CHRO (Chromocell Therapeutics): analytical breakdowns and indicator data

Investors are seeking assets with proven financial stability. This indicator measures the daily change in the growth rate of net earnings per share over a rolling year. For the biopharmaceutical company Chromocell Therapeutics (CHRO), such calculations are critical due to the colossal costs associated with clinical trials and the patenting of signal blocking methods. The negative trend here reflects the cost of the scientific barrier. Assess capital risks via the annual EPS growth based on trailing twelve months (TTM) financial statements.